Last updated: 2026-09-14 00:59:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Decoy Therapeutics Inc. (DCOY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.70, with a market capitalization of $1.75M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.60 to $16.92. This page covers its latest market performance, valuation, price trends and company information.
$1.75M | |
$2.75 | |
$16.92 | |
$2.60 | |
$2.73 | |
22.37K | |
250.97K | |
-- | |
$16.92 | |
$2.60 | |
-- | |
-- |
Decoy Therapeutics Inc. (DCOY) last closed at $2.73 as of 2026-09-11 23:57:00, unchanged from the previous close of $2.73.
During the latest regular trading session, DCOY traded between $2.60 and $16.92, with a volume of 22.37K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Decoy Therapeutics Inc. (DCOY) moved from $2.98 to $2.70, representing a decline of 9.40% ($0.28).
The stock traded between $2.60 and $3.08 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 24.82 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.7%
DCOY is currently trading at $2.70, placing it 0.7% of the way from its 52-week low of $2.60 to its 52-week high of $16.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 11 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Decoy Therapeutics Inc. (DCOY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.